RedHill Biopharma (RDHL) Interest & Investment Income (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Interest & Investment Income data on file, last reported at $1.3 billion in Q2 2025.

• Interest & Investment Income for Q2 2025 came in at $1.3 billion, down 81.31% year-over-year; the trailing twelve-month figure through Jun 2025 was $1.3 billion (down 81.31% YoY), and the FY2025 annual result was $1.3 million, down 84.21% from the prior year.
• Interest & Investment Income eased to $1.3 billion in Q2 2025 per RDHL's latest filing, from $7.2 billion in the prior quarter.
• Over five years, Interest & Investment Income peaked at $7.2 billion in Q2 2024 and troughed at $10000.0 in Q1 2022.
• A 5-year average of $855.2 million and a median of $3.3 million in 2022 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2021 and 2023: Interest & Investment Income tumbled 90.37% in 2021, then soared 215720.0% in 2023.
• A 5-year view of Interest & Investment Income shows it stood at $39000.0 in 2021, then surged by 12366.67% to $4.9 million in 2022, then soared by 489.82% to $28.7 million in 2023, then jumped by 24857.28% to $7.2 billion in 2024, then sank by 81.31% to $1.3 billion in 2025.
• Business Quant data shows RDHL's Interest & Investment Income at $1.3 billion in Q2 2025, $7.2 billion in Q2 2024, and $28.7 million in Q2 2023.